Singapore Markets open in 7 hrs 23 mins

Orphazyme A/S (ORPH)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.87000.0000 (0.00%)
As of 04:00PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.75
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 377.7700
52-week low 30.3700
50-day moving average 31.2772
200-day moving average 33.3144

Share statistics

Avg vol (3-month) 31.36M
Avg vol (10-day) 3514.04k
Shares outstanding 534.95M
Implied shares outstanding 6N/A
Float 828.15M
% held by insiders 10.00%
% held by institutions 12.95%
Shares short (14 Dec 2021) 4104.77k
Short ratio (14 Dec 2021) 40.15
Short % of float (14 Dec 2021) 4N/A
Short % of shares outstanding (14 Dec 2021) 40.30%
Shares short (prior month 14 Nov 2021) 4619.11k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in DKK.

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Jun 2021


Profit margin 0.00%
Operating margin (ttm)-5,922.12%

Management effectiveness

Return on assets (ttm)-88.16%
Return on equity (ttm)-251.34%

Income statement

Revenue (ttm)13.15M
Revenue per share (ttm)0.40
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -762.23M
Net income avi to common (ttm)-845.61M
Diluted EPS (ttm)-3.8830
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)334.18M
Total cash per share (mrq)9.56
Total debt (mrq)58.59M
Total debt/equity (mrq)35.13
Current ratio (mrq)1.80
Book value per share (mrq)4.77

Cash flow statement

Operating cash flow (ttm)-716.63M
Levered free cash flow (ttm)-392.38M